STAGE III ANAL CANCER AJCC V8
Clinical trials for STAGE III ANAL CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE III ANAL CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE III ANAL CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope: personalized therapy for HIV patients with anal cancer
Disease control OngoingThis study tests a personalized approach for people with HIV and anal cancer. For low-risk patients, standard chemotherapy and radiation are used. For high-risk patients, the immunotherapy drug nivolumab is added after standard treatment to help prevent the cancer from coming bac…
Matched conditions: STAGE III ANAL CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 10:14 UTC
-
Immunotherapy combo shows promise in advanced anal cancer trial
Disease control OngoingThis study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy works better than chemotherapy alone for people with anal cancer that has spread or cannot be removed. About 205 adults with this type of cancer will receive either the combination or just c…
Matched conditions: STAGE III ANAL CANCER AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 09:35 UTC
-
Immunotherapy after Chemo-Radiation may keep anal cancer at bay
Disease control OngoingThis study tests whether adding the immunotherapy drug nivolumab after standard chemoradiation helps prevent anal cancer from coming back in patients with high-risk stage II-III disease. About 344 adults with certain types of anal cancer will receive nivolumab or a placebo for up…
Matched conditions: STAGE III ANAL CANCER AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 09:34 UTC